Eli Lilly and Company (NYSE:LLY) Stock Holdings Reduced by Lockerman Financial Group Inc.

Lockerman Financial Group Inc. cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 619 shares of the company’s stock after selling 17 shares during the period. Lockerman Financial Group Inc.’s holdings in Eli Lilly and Company were worth $478,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Clear Harbor Asset Management LLC raised its position in Eli Lilly and Company by 244.3% during the fourth quarter. Clear Harbor Asset Management LLC now owns 1,973 shares of the company’s stock valued at $1,523,000 after acquiring an additional 1,400 shares in the last quarter. ADE LLC increased its stake in shares of Eli Lilly and Company by 6.2% during the 4th quarter. ADE LLC now owns 275 shares of the company’s stock worth $212,000 after purchasing an additional 16 shares during the last quarter. Charles Schwab Trust Co raised its holdings in shares of Eli Lilly and Company by 42.0% during the 4th quarter. Charles Schwab Trust Co now owns 321 shares of the company’s stock valued at $248,000 after purchasing an additional 95 shares in the last quarter. Ballentine Partners LLC lifted its stake in shares of Eli Lilly and Company by 1.6% in the 4th quarter. Ballentine Partners LLC now owns 17,260 shares of the company’s stock valued at $13,325,000 after purchasing an additional 279 shares during the last quarter. Finally, Atwood & Palmer Inc. boosted its holdings in Eli Lilly and Company by 3.9% in the fourth quarter. Atwood & Palmer Inc. now owns 532 shares of the company’s stock worth $411,000 after purchasing an additional 20 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $753.65 on Thursday. Eli Lilly and Company has a twelve month low of $614.82 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a market cap of $715.46 billion, a P/E ratio of 81.48, a PEG ratio of 1.52 and a beta of 0.41. The company’s 50-day simple moving average is $777.46 and its 200 day simple moving average is $851.61.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 earnings per share. As a group, research analysts forecast that Eli Lilly and Company will post 12.98 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Bank of America reaffirmed a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Citigroup upped their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Barclays decreased their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Finally, Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.